港股公告掘金 | 零跑汽车发布中期业绩，股东应占溢利2.08亿元同比增加530.97%_老虎社区_美港股上老虎

港股公告掘金 | 零跑汽车发布中期业绩，股东应占溢利2.08亿元同比增加530.97%

智通财经08-25

重大事项：维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理立德教育(01449)与NeuralFin同意于人工智能(AI)教育领域建立战略合作关系上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权宝济药业-B(02659...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/2662720731?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-25 09:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662720731","market":"us","top_or_hot":-1,"title":"港股公告掘金 | 零跑汽车发布中期业绩，股东应占溢利2.08亿元 同比增加530.97%","media":"智通财经","content":"<div>\n<p>重大事项：维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理立德教育(01449)与NeuralFin同意于人工智能(AI)教育领域建立战略合作关系上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权宝济药业-B(02659...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1484782.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 零跑汽车发布中期业绩，股东应占溢利2.08亿元 同比增加530.97%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 零跑汽车发布中期业绩，股东应占溢利2.08亿元 同比增加530.97%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-25 09:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1484782.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>重大事项：维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理立德教育(01449)与NeuralFin同意于人工智能(AI)教育领域建立战略合作关系上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权宝济药业-B(02659...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1484782.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1484782.html","article_id":"2662720731","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662720731","pubTimestamp":1787620280,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：维立志博-B(09887)：维利信(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理立德教育(01449)与NeuralFin同意于人工智能(AI)教育领域建立战略合作关系上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权宝济药业-B(02659)","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","03310":"云英谷科技","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1119":"汽车制造商","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK1163":"半导体产品","02256":"和誉-B","BK1219":"保健护理服务","BK1141":"生命科学工具和服务","02268":"药明合联","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1161":"生物科技","09863":"零跑汽车","KCAI":"KraneShares China Alpha Index ETF","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","02661":"轻松健康","BK4585":"ETF&股票定投概念","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC"},"translate_title":"Hong Kong Stock Announcement Nuggets | Leapmotor released interim results, profit attributable to shareholders of 208 million yuan, a year-on-year increase of 530.97%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":0.9,"09863":1.5,"02661":0.9,"03310":0.9,"KCAI":1.5,"02268":0.9,"VXUS":1.5},"content_text":"重大事项：维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理立德教育(01449)与NeuralFin同意于人工智能(AI)教育领域建立战略合作关系上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权宝济药业-B(02659)：KJ015注射液(抗HER2双特异性抗体皮下制剂)临床试验申请获得美国FDA许可长风药业(02652)：ICF001于获国家药监局临床试验默示许可后扩大适应症范围小鹏集团-W(09868)：鹏行获IDG资本、阿里巴巴、腾讯及高榕创投认购6亿美元鹏行A系列优先股经营业绩：云英谷科技(03310)发布中期业绩，收入3.18亿元 深耕品牌AMOLED显示驱动芯片市场和誉-B(02256)上半年核心药物贝捷迈®成功商业化 研发开支持续加码轻松健康(02661)中报：综合健康服务收入增长273.5%，医疗AI加快走向应用中国通号(03969)公布中期业绩 归母净利约14.73亿元同比减少9.07%立讯精密(02475)公布中期业绩 归母净利润约78.43亿元 同比增长18.04%佳兆业美好(02168)发布中期业绩，股东应占溢利4187.3万元 同比减少12.4%中国船舶租赁(03877)发布中期业绩，股东应占溢利12.22亿港元，同比增长10.6%药明合联(02268)公布中期业绩 公司拥有人应占经调整纯利约10.27亿元 同比增长37.4%小鹏集团-W(09868)发布中期业绩 股东应占净亏损31.21亿元 同比扩大173.35%汇量科技(01860)发布2026年中期业绩：收入 11.56 亿美元，同比增长 23.2 %零跑汽车(09863)发布中期业绩，股东应占溢利2.08亿元 同比增加530.97%中国民航信息网络(00696)发布中期业绩，归母净利润15.43亿元 同比增加6.59%鸣鸣很忙(01768)发布中期业绩，归母利润22.4亿元 同比增加155.39%越秀服务(06626)发布中期业绩，股东应占盈利2.24亿元 全方位优化增值服务业态布局华润医药(03320)发布中期业绩，股东应占溢利21.87亿元，同比增长5.3%思格新能(06656)公布中期业绩 经调整净利润约24.85亿元 同比增长135.8%","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}